Your browser doesn't support javascript.
loading
The Risk Function of Breast and Ovarian Cancers in the Avrami-Dobrzynski Cellular Phase-Transition Model.
Zawadzka, Anna; Brzozowska, Beata; Matyjanka, Anna; Mikula, Michal; Reszczynska, Joanna; Tartas, Adrianna; Fornalski, Krzysztof W.
Afiliación
  • Zawadzka A; Maria Sklodowska-Curie National Research Institute of Oncology (NIO-MSCI), 02-781 Warsaw, Poland.
  • Brzozowska B; Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland.
  • Matyjanka A; Faculty of Physics, Warsaw University of Technology, 00-662 Warsaw, Poland.
  • Mikula M; Maria Sklodowska-Curie National Research Institute of Oncology (NIO-MSCI), 02-781 Warsaw, Poland.
  • Reszczynska J; Mossakowski Medical Research Institute, Polish Academy of Sciences (IMDiK PAN), 02-106 Warsaw, Poland.
  • Tartas A; Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland.
  • Fornalski KW; Faculty of Physics, Warsaw University of Technology, 00-662 Warsaw, Poland.
Int J Mol Sci ; 25(2)2024 Jan 22.
Article en En | MEDLINE | ID: mdl-38279352
ABSTRACT
Specifying the role of genetic mutations in cancer development is crucial for effective screening or targeted treatments for people with hereditary cancer predispositions. Our goal here is to find the relationship between a number of cancerogenic mutations and the probability of cancer induction over the lifetime of cancer patients. We believe that the Avrami-Dobrzynski biophysical model can be used to describe this mechanism. Therefore, clinical data from breast and ovarian cancer patients were used to validate this model of cancer induction, which is based on a purely physical concept of the phase-transition process with an analogy to the neoplastic transformation. The obtained values of model parameters established using clinical data confirm the hypothesis that the carcinogenic process strongly follows fractal dynamics. We found that the model's theoretical prediction and population clinical data slightly differed for patients with the age below 30 years old, and that might point to the existence of an ancillary protection mechanism against cancer development. Additionally, we reveal that the existing clinical data predict breast or ovarian cancers onset two years earlier for patients with BRCA1/2 mutations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza